Table 6.

IC₅₀ (μM) for 4a–j and 6a–e against the tested cancer cell lines.

Compound	MCF-7	A549	HCT-116
4a	14.36 ± 0.87	22.36 ± 1.39	16.65 ± 1.09
4b	12.57 ± 1.41	19.73 ± 2.18	13.85 ± 1.44
4c	13.11 ± 2.05	22.13 ± 1.58	15.49 ± 1.72
4d	14.06 ± 1.13	22.95 ± 1.36	16.43 ± 2.11
4e	5.76 ± 1.53	10.45 ± 1.04	15.67 ± 1.68
4f	5.42 ± 1.40	10.23 ± 1.77	16.88 ± 0.85
4g	6.31 ± 1.08	11.79 ± 1.82	16.09 ± 1.67
4h	7.95 ± 1.95	7.82 ± 1.66	13.94 ± 1.18
4i	13.07 ± 1.64	14.55 ± 1.62	18.16 ± 1.30
4j	10.63 ± 1.77	12.87 ± 2.03	17.39 ± 1.84
6a	20.42 ± 1.39	27.48 ± 0.98	10.15 ± 0.97
6b	23.55 ± 1.45	25.65 ± 1.19	9.26 ± 1.51
6c	21.13 ± 1.73	24.29 ± 1.50	8.22 ± 1.25
6d	22.84 ± 0.97	26.56 ± 1.82	8.55 ± 1.17
6e	28.65 ± 2.16	30.25 ± 1.33	13.89 ± 1.48
Sorafenib	5.84 ± 0.87	9.63 ± 1.12	7.56 ± 1.08